Head and neck oncology research evaluates organ-preserving therapies, immunotherapy combinations, and HPV-stratified treatment paradigms.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
Related topics: Fixed-Duration and De-escalated Therapy
Please enable JavaScript to access the latest cancer research articles and studies.